Adjuvant chemotherapy for non-small-cell lung cancer - The smoke clears

New England Journal of Medicine

Volumn 352, Issue 25, 2005, Pages 2640-2642

  Pisters, Katherine M W ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM; TEGAFUR; URACIL; DRUG DERIVATIVE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CLINICAL FEATURE; DISEASE COURSE; EDITORIAL; FOLLOW UP; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; PRIORITY JOURNAL; RECURRENT DISEASE; SMOKE; SURVIVAL RATE; LUNG TUMOR; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; HUMANS; LUNG NEOPLASMS; VINBLASTINE;

EID: 20544452751     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe058110     Document Type: Editorial

References (12)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-97.
3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
4. Burdett S, Stewart L. Postoperative radiotherapy in non-smallcell lung cancer: update on an individual patient data meta-analysis. Lung Cancer 2005;47:81-3.
5. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
6. Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N Engl J Med 2000;343:1217-22.
7. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA nonsmall-cell lung cancer. J Natl Cancer Inst 2003;95:1453-61.
8. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-60.
9. Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol 2004;22:Suppl 14S:621s. abstract.
10. Douillard J-Y, Rosell R, Delena M, et al. ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I-III) non-small cell lung cancer patients: final results after 70-month median follow-up. J Clin Oncol 2005;23: Suppl 16S:624s. abstract.
11. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004;350:1713-21.
12. Hamada C, Ohta M, Wada H, et al. Survival benefit of oral UFT of adjuvant chemotherapy after completely resected non-small cell lung cancer. J Clin Oncol 2004;22:Suppl 14S:617s. abstract.